Commit and Lymphadenocyst - a phase IV clinical study of FDA data
Summary:
We study 4,847 people who take Commit (nicotine polacrilex) or have Lymphadenocyst. No report of Lymphadenocyst is found in people who take Commit.
The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.
What is Commit?
Commit has active ingredients of nicotine polacrilex. eHealthMe is studying from 4,842 Commit users. Check the latest studies of Commit.
What is Lymphadenocyst?
Lymphadenocyst (proliferative process that results in enlargement of lymph nodes) is found to be associated with 1 drug and 1 condition by eHealthMe. Check the latest studies of Lymphadenocyst.
No report is found.
Do you take Commit and have Lymphadenocyst?
- Check whether Lymphadenocyst is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Commit:
- Commit (4,842 reports)
Lymphadenocyst treatments and more:
- Lymphadenocyst (5 reports)
How severe was Lymphadenocyst and when was it recovered:
Expand to all the drugs that have ingredients of nicotine polacrilex:
Browse all side effects of Commit:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Lymphadenocyst:
Browse all the conditions that are associated with Lymphadenocyst:
How the study uses the data?
The study uses data from the FDA. It is based on nicotine polacrilex (the active ingredients of Commit) and Commit (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Gilenya and Memory Impairment for Men aged 20-29 - a second ago
- Gilenya and Memory Aids for Men aged 20-29 - 2 seconds ago
- Muscle Atrophy and drugs of ingredients of etoposide - 2 seconds ago
- Gilenya and Long-Term Memory Loss for Men aged 20-29 - 2 seconds ago
- Gilenya and Sudden Memory Loss for Men aged 20-29 - 2 seconds ago
- Gilenya and Temporal Memory Loss for Men aged 20-29 - 2 seconds ago
- Gilenya and Short-Term Memory Loss for Men aged 20-29 - 3 seconds ago
- Gilenya and Loss Of Memory for Men aged 20-29 - 3 seconds ago
- Gilenya and Impaired Memory for Men aged 20-29 - 3 seconds ago
- Gilenya and Forgetfulness for Men aged 20-29 - 4 seconds ago